Company / Cash & Equivalents
SUTRO BIOPHARMA, INC. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$58.1M
FY2025
5-year range
$30.4M / $206.2M
FY2021-FY2025
Trend
-69.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $5M in FY2020 to $206M in FY2021.
Based on SEC 10-K filings.
$58M in FY2025 with a 5-year CAGR of +63.6%.
Improved from $47M to $58M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- +63.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +63.6%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 69.5% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.1M | -69.5% |
| FY2024 | $190.3M | +302.7% |
| FY2023 | $47.3M | +55.4% |
| FY2022 | $30.4M | -85.2% |
| FY2021 | $206.2M | +4056.3% |
| FY2020 | $5.0M | -96.0% |
| FY2019 | $125.3M | +469.0% |
| FY2018 | $22.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026